NCT03448718 - Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

July 14, 2021

Study Completion Date

October 15, 2021

Conditions

Metastatic Urothelial Cancer

Interventions

DRUG

Olaparib

1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of \> 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.

Trial Locations (7)

21287

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

27599

University of North Carolina at Chapel Hill, Chapel Hill

37232

Vanderbilt-Ingran Cancer Center, Nashville

48201

Karmanos Cancer Center (Wyane State University), Detroit

60637

University of Chicago Medical Center, Chicago

10029-6542

Icahn School of Medicine at Mount Sinai, New York

84112-5550

Huntsman Cancer Institute University of Utah, Salt Lake City